María Guzmán-Fulgencio1, Juan Berenguer2,3, María Angeles Jiménez-Sousa1, Dariela Micheloud4, Mónica García-Álvarez1, José María Bellón5, Teresa Aldámiz-Echevarría2,3, Pilar García-Broncano1, Pilar Catalán6, Cristina Diez2,3, Daniel Pineda-Tenor1, Salvador Resino1. 1. Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. 2. Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. 3. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. 4. Servicio de Medicina Interna, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. 5. Fundación para la investigación Biomédica del Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. 6. Servicio de Microbiología, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain.
Abstract
BACKGROUND: The IL7RA polymorphisms have recently been associated with CD4+ T-cell decline in untreated HIV-infected subjects and CD4+ T-cell recovery in patients on combination antiretroviral therapy (cART). The aim of this study was to evaluate whether IL7RA polymorphisms are associated with CD4+ T-cell recovery in HIV-infected patients on long-term cART. STUDY DESIGN: We performed a retrospective study in 151 naïve cART patients with severe immunodeficiency (CD4+ counts ≤200 cells/mm(3) ). IL7RA polymorphisms' genotyping was performed using Sequenom's MassARRAY platform. The outcome variable was the time to achieve the first value of CD4+ count ≥500 cells/mm(3) during the follow-up. RESULTS: Two different trends of CD4+ T-cell recovery were found in Kaplan-Meier analysis. During the first 48 months, 60 of 151 (39·7%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , and no differences were observed between IL7RA genotypes. After the first 48 months of follow-up, 27 of 151 (17·8%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , with a different pattern of CD4+ recovery depending on IL7RA genotype. Patients with rs10491434 TT genotype and rs6897932 TT genotype were more likely of achieving CD4+ value ≥500 cells/mm(3) than patients with rs10491434 CT/CC genotype (adjusted hazard ratio (aHR) = 3·59; P = 0·005) and patients with rs6897932 CC/CT genotype (aHR = 11·7; P < 0·001). CONCLUSIONS: The IL7RA polymorphisms seem to be associated with CD4+ T-cell recovery in HIV-infected patients who started cART with severe immunodeficiency, in the second phase of CD4+ T-cell recovery after long-term cART.
BACKGROUND: The IL7RA polymorphisms have recently been associated with CD4+ T-cell decline in untreated HIV-infected subjects and CD4+ T-cell recovery in patients on combination antiretroviral therapy (cART). The aim of this study was to evaluate whether IL7RA polymorphisms are associated with CD4+ T-cell recovery in HIV-infectedpatients on long-term cART. STUDY DESIGN: We performed a retrospective study in 151 naïve cART patients with severe immunodeficiency (CD4+ counts ≤200 cells/mm(3) ). IL7RA polymorphisms' genotyping was performed using Sequenom's MassARRAY platform. The outcome variable was the time to achieve the first value of CD4+ count ≥500 cells/mm(3) during the follow-up. RESULTS: Two different trends of CD4+ T-cell recovery were found in Kaplan-Meier analysis. During the first 48 months, 60 of 151 (39·7%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , and no differences were observed between IL7RA genotypes. After the first 48 months of follow-up, 27 of 151 (17·8%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , with a different pattern of CD4+ recovery depending on IL7RA genotype. Patients with rs10491434 TT genotype and rs6897932 TT genotype were more likely of achieving CD4+ value ≥500 cells/mm(3) than patients with rs10491434 CT/CC genotype (adjusted hazard ratio (aHR) = 3·59; P = 0·005) and patients with rs6897932 CC/CT genotype (aHR = 11·7; P < 0·001). CONCLUSIONS: The IL7RA polymorphisms seem to be associated with CD4+ T-cell recovery in HIV-infectedpatients who started cART with severe immunodeficiency, in the second phase of CD4+ T-cell recovery after long-term cART.
Authors: Clara Restrepo; Mónica Gutierrez-Rivas; Yolanda M Pacheco; Marcial García; Julià Blanco; Luz M Medrano; María A Navarrete-Muñoz; Félix Gutiérrez; Pilar Miralles; David Dalmau; Juan Luis Gómez; Miguel Górgolas; Alfonso Cabello; Salvador Resino; José M Benito; Norma Rallón Journal: PLoS One Date: 2019-03-28 Impact factor: 3.240
Authors: Salvador Resino; María A Navarrete-Muñoz; Julià Blanco; Yolanda M Pacheco; Iván Castro; Juan Berenguer; Jesús Santos; Francisco J Vera-Méndez; Miguel Górgolas; M A Ángeles Jiménez-Sousa; José M Benito; Norma Rallón Journal: Biomolecules Date: 2019-06-16
Authors: María Ángeles Jiménez-Sousa; Ana Zaida Gómez-Moreno; Daniel Pineda-Tenor; Luz Maria Medrano; Juan José Sánchez-Ruano; Amanda Fernández-Rodríguez; Tomas Artaza-Varasa; José Saura-Montalbán; Sonia Vázquez-Morón; Pablo Ryan; Salvador Resino Journal: PLoS One Date: 2018-05-09 Impact factor: 3.240